DK1592384T3 - Cop 1 til behandling af inflammatoriske tarmsygdomme - Google Patents

Cop 1 til behandling af inflammatoriske tarmsygdomme

Info

Publication number
DK1592384T3
DK1592384T3 DK04703462.4T DK04703462T DK1592384T3 DK 1592384 T3 DK1592384 T3 DK 1592384T3 DK 04703462 T DK04703462 T DK 04703462T DK 1592384 T3 DK1592384 T3 DK 1592384T3
Authority
DK
Denmark
Prior art keywords
cop
treatment
inflammatory bowel
bowel diseases
diseases
Prior art date
Application number
DK04703462.4T
Other languages
English (en)
Inventor
Rina Aharoni
Ruth Arnon
Basak Kayhan
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK1592384T3 publication Critical patent/DK1592384T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04703462.4T 2003-01-21 2004-01-20 Cop 1 til behandling af inflammatoriske tarmsygdomme DK1592384T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44113603P 2003-01-21 2003-01-21
PCT/IL2004/000054 WO2004064717A2 (en) 2003-01-21 2004-01-20 Cop 1 for treatment of inflammatory bowel diseases

Publications (1)

Publication Number Publication Date
DK1592384T3 true DK1592384T3 (da) 2012-12-17

Family

ID=32771907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04703462.4T DK1592384T3 (da) 2003-01-21 2004-01-20 Cop 1 til behandling af inflammatoriske tarmsygdomme

Country Status (14)

Country Link
US (1) US8008258B2 (da)
EP (1) EP1592384B1 (da)
AU (1) AU2004206120B2 (da)
CA (1) CA2513567C (da)
DK (1) DK1592384T3 (da)
ES (1) ES2397836T3 (da)
MX (1) MXPA05007711A (da)
NO (1) NO333579B1 (da)
NZ (1) NZ569331A (da)
PT (1) PT1592384E (da)
RU (1) RU2339397C2 (da)
SI (1) SI1592384T1 (da)
WO (1) WO2004064717A2 (da)
ZA (1) ZA200505733B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
ATE475883T1 (de) * 2001-12-04 2010-08-15 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
NZ551236A (en) * 2004-05-07 2010-11-26 Peptimmune Inc Methods of treating disease with random copolymers
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
WO2006083608A1 (en) * 2005-02-02 2006-08-10 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2732228A1 (en) * 2008-07-25 2010-01-28 The Johns Hopkins University Methods and compositions for treating and preventing autoimmune diseases
PL2949335T3 (pl) 2009-08-20 2017-07-31 Yeda Research & Development Company, Ltd. Terapia octanem glatirameru podawanym z niewielką częstotliwością
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
KR101916853B1 (ko) 2010-07-26 2018-11-09 큐 바이올로직스 인코포레이티드 면역원성 소염 조성물
EP2627669B1 (en) 2010-10-11 2016-08-17 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
EA201490749A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
NZ630421A (en) 2012-10-10 2018-07-27 Teva Pharma Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
RU2020120075A (ru) 2014-05-02 2020-07-03 Кью Байолоджикс Инк. Противомикробная иммуномодуляция
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US20210220428A1 (en) 2016-06-30 2021-07-22 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
JP7000458B2 (ja) 2017-05-15 2022-02-10 ステム セル メディスン リミテッド 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療
CA3062123A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
IL140592A0 (en) * 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) * 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
DK2239269T3 (da) 1998-09-25 2013-04-29 Yeda Res & Dev Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører
WO2000020010A1 (en) * 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
EP1128839A4 (en) * 1998-11-12 2002-10-09 Yeda Res & Dev PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD
AU3108001A (en) * 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
AU2001238469C1 (en) * 2000-02-18 2006-08-24 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
AU2003204344A1 (en) * 2002-05-23 2003-12-11 Milder, Dan George Compositions and methods for the treatment of autoimmune diseases and neurological disorders
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe

Also Published As

Publication number Publication date
CA2513567C (en) 2012-10-23
NZ569331A (en) 2010-08-27
EP1592384A4 (en) 2008-12-31
EP1592384A2 (en) 2005-11-09
NO20053860L (no) 2005-10-20
RU2005126412A (ru) 2006-01-27
PT1592384E (pt) 2013-01-28
NO333579B1 (no) 2013-07-15
US8008258B2 (en) 2011-08-30
EP1592384B1 (en) 2012-10-31
RU2339397C2 (ru) 2008-11-27
ZA200505733B (en) 2006-10-25
US20060264354A1 (en) 2006-11-23
ES2397836T3 (es) 2013-03-11
AU2004206120B2 (en) 2009-09-24
MXPA05007711A (es) 2005-09-30
WO2004064717A3 (en) 2005-10-13
SI1592384T1 (sl) 2013-03-29
NO20053860D0 (no) 2005-08-18
CA2513567A1 (en) 2004-08-05
AU2004206120A1 (en) 2004-08-05
WO2004064717A2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
DK1592384T3 (da) Cop 1 til behandling af inflammatoriske tarmsygdomme
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
NO20031443D0 (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
CY2013021I1 (el) Συνθεσεις για τη θεραπευτικη αγωγη γαστροεντερικων διαταραχων
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
NO20031442L (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
NO20054598D0 (no) Beta-karboliner anvendbare for behandling av betennelsessykdommer
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
IS8246A (is) Meðferð á taugahrörnunarástandi
DK1643998T3 (da) NK1/NK3-antagonister til behandling af skizofreni
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
EP1592384A3 (en) Cop 1 for treatment of inflammatory bowel diseases
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DE602004014547D1 (de) Funduskamera
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
EP1611120A4 (en) NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme